Atlas Trials

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Clinical trial NCT00250874 · UNKNOWN

Trial details

NCT number
NCT00250874
Sponsor
Zeneus Pharma
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2003-12-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.